Recent content by Joxy

T&R Biofab is coming from South Korea and they are very well established in the world of bioprinting artificial organs with their unique 3D bioprinting technology. T&R Biofab patents 3D printing-based hair follicle spheroid manufacturing technology - Expected to be an innovative...

In the case of organoids, a next-generation therapeutic, the company received a preliminary meeting request from a major global pharmaceutical company, followed by a second meeting in the U.S. In particular, the company shared specific research results of a dermal organoid-based hair transplant...

Vast majority of worldwide population 60-70 years ago lived in very poor conditions with deficit of enough food. That’s why many of them were so skinny. Now you have food stores on every corner 24/7 and vast majority of people can afford food as many they want. Basically, you eat far more food...

Running up a company cost a LOT OF money, running up a clinical trials cost a LOT OF money, building infrastructure to deliver your product cost a LOT OF money. Nothing is free and nothing is cheap in biopharma industry. So, promoting company on big events is big plus for getting more...

Next Era Biotechnology AWARD At the WSJ-sponsored "The Future of Everything 2024" Next Era Leaders AWARD ceremony held in New York, our company's Kondo was awarded the "Next Era Biotechnology AWARD" category. In addition, the award ceremony will be broadcast on Nikkei CNBC's program "New Wave...

Better living conditions and better diet can play role about your skin/hair/teeth and height, but genetics play the most important part. How people get older they loose height and became smaller and it became difficult to loose weight. Just look at the junkies/drug addicts. Most of them have...

Most people are fat, because they don’t care and because society glorify fatness. Plus, sedentary jobs and available food at any time. Not because of Western diet. I eat Western diet, and I am not fat.

Kangstem Biotech signed a MOU (memorandum of understanding) with HLB BioStep and HLB BioCode on the 23rd to establish an organoid-based drug safety and efficacy evaluation platform and develop cell therapy drugs. Through this MOU, the three companies plan to pursue the commercialization of...

Kang Stem Biotech pursues commercialization of HLB Biostep and alternative animal testing methods... “Signed MOU for organoid-based research and development” https://kangstem.com/pr/ir_news/view?i=641 This is interesting new paper published by Dr. Kyung - Sun Kang, professor at Seoul...

It will be same like with teeth regeneration, skin regeneration, obesity/overweight products. You have many options about teeth today and still many people walk with bad teeth or without teeth. Or you have gyms on every corner today, but people getting more fat. That is reality. Many people...

OrganTech CEO Takashi Kondo put update on his LinkedIn profile: “We raised 4.3M US dollars fund through private placement in 2023.OrganTech restarted our business and R&D.In 2024, we made out licensing contracts and collaboration research contracts with some partners.Our revenue is going to...

Of course he will not say publicly that it is not possible.

Why?

It is not correct translation. Japanese language is pretty hard and one sentence can have different meaning.

Can anyone translate this? Anyone familiar with Japanese? OrganTech and Takashi Tsuji co-wrote this article. https://www.organ-tech.jp/assets/240326-newton.pdf